

1 **Low levels of monkeypox virus neutralizing antibodies after MVA-BN** 2 **vaccination in healthy individuals**

3

4 Luca M. Zaeck^{1#}, Mart M. Lamers^{1#}, Babs E. Verstrepen^{1#}, Theo M. Bestebroer¹, Martin E. van
5 Royen², Hannelore Götz³, Marc C. Shamier¹, Leanne P.M. van Leeuwen¹, Katharina S.
6 Schmitz¹, Kimberley Alblas¹, Suzanne van Efferen¹, Susanne Bogers¹, Sandra Scherbeijn¹,
7 Guus F. Rimmelzwaan⁴, Eric C.M. van Gorp¹, Marion P.G. Koopmans^{1§}, Bart L. Haagmans^{1§},
8 Corine H. GeurtsvanKessel^{1\$*}, and Rory D. de Vries^{1§}

9

10 ¹ *Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands*

11 ² *Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands*

12 ³ *Department Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond (GGD Rotterdam),
13 Rotterdam, the Netherlands*

14 ⁴ *Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover,
15 Germany*

16

17 # authors contributed equally

18 § authors contributed equally

19 * corresponding author: Corine H. GeurtsvanKessel, c.geurtsvankessel@erasmusmc.nl

20

21 **Abstract (239 words)**

22 In July 2022, the ongoing monkeypox (MPX) outbreak was declared a public health
23 emergency of international concern by the World Health Organization. Modified vaccinia virus
24 Ankara (MVA-BN, also known as Imvamune, Jynneos, or Imvanex) is a 3rd generation
25 smallpox vaccine that was generated by serial passaging of the more pathogenic parental
26 vaccinia virus (VACV), and is authorized as a vaccine against MPX in humans in a two-shot
27 regimen. Up to now, there is a lack of data that demonstrate MPX virus (MPXV)-neutralizing
28 antibodies in vaccinated individuals and vaccine efficacy data against MPXV infection. Here,
29 we measure MVA-, VACV-, and MPXV-reactive binding and neutralizing antibodies with
30 validated in-house assays in cohorts of historically smallpox-vaccinated, MPXV PCR-positive,
31 and recently MVA-BN-vaccinated individuals. We show that MPXV neutralizing antibodies
32 were detected across all cohorts in individuals with MPXV exposure as well as those who
33 received historic (VACV) vaccination. However, a primary MVA-BN immunization series in
34 non-primed individuals yields relatively low levels of MPXV neutralizing antibodies. As the role
35 of MPXV neutralizing antibodies for protection against disease and transmissibility is currently
36 unclear and no correlate of protection against MPXV infection has been identified yet, this
37 raises the question how well vaccinated individuals are protected. Dose-sparing leads to lower
38 antibody levels, whereas a third MVA vaccination further boosts the antibody response. Cohort
39 studies following vaccinated individuals are necessary to further assess vaccine efficacy in
40 risk populations and determine correlates of protection for this emerging pathogen.

41

42 Introduction

43 Monkeypox virus (MPXV) belongs to the Orthopoxvirus genus of the Poxviridae family of large
44 double-stranded DNA viruses, and causes a zoonotic disease known as monkeypox (MPX).
45 In May 2022, MPX was identified in several countries in which MPX cases had not been
46 reported previously, after which MPXV rapidly spread in Europe and the United States among
47 individuals who had not traveled to endemic areas.¹ On July 23, 2022, this ongoing MPX
48 outbreak was declared a public health emergency of international concern (PHEIC) by the
49 World Health Organization (WHO).²

50

51 MPXV is closely related to variola virus (VARV), the causative agent of smallpox. Smallpox
52 was eradicated by the use of different attenuated poxvirus vaccines combined with active case
53 finding, isolation, and quarantine measures. The 1st and 2nd generation smallpox vaccines
54 contained infectious vaccinia virus (VACV) grown either in the skin of live animals, the
55 chorioallantoic membrane of eggs, or cell culture. The 3rd generation smallpox vaccine was
56 based on an even further attenuated VACV obtained by serial passage in chicken embryo
57 fibroblasts (CEF), known as modified vaccinia virus Ankara (MVA). Since MVA was developed
58 in the endgame of smallpox eradication (first market authorization was obtained in Germany
59 in 1977),³ efficacy against smallpox has been inferred based on the noninferiority of
60 immunogenicity in clinical studies.⁴ A study in the Democratic Republic of the Congo showed
61 that the VACV smallpox vaccine was effective against MPX to a certain extent.⁵ Efficacy data
62 of the 3rd generation MVA smallpox vaccine against MPX in humans is lacking. MVA
63 vaccination afforded protection against severe MPX disease and death in non-human
64 primates by inducing both antibodies and T-cells, but sterile immunity was not achieved and
65 some skin lesions remained.⁶⁻⁸ Partly because of this evidence for protection from severe
66 disease, MVA-BN (named after manufacturer Bavarian Nordic) was licensed as a vaccine
67 against MPX in humans in Canada (known as Imvamune) and the United States (known as
68 Jynneos), and was recently approved by the European Medicines Agency (EMA) 'under
69 special circumstances' (known as Imvanex), despite a lack of efficacy data against human
70 MPXV infection or demonstrable MPXV-neutralizing antibodies in vaccinated individuals.

71

72 Randomized trials, 'test-negative' studies, and cohort studies are being initiated to better
73 understand MVA-BN efficacy against MPX.⁹ While these studies are underway, it is equally
74 important to better understand the immunogenicity of MVA, especially with regards to MPXV.
75 Assays to measure VACV- and MVA-binding antibodies have been previously developed in
76 ELISA formats using purified intracellular mature virions (IMV) or infected cell lysates.^{6,10}
77 Functional antibody measurements through virus neutralization assays using VACV or MVA

78 expressing reporter proteins have been used for studies assessing the noninferiority of
79 vaccine-induced immunogenicity between new- and old-generation vaccines.^{6,10,11} However,
80 assays to measure MPXV-specific antibodies are lacking. Here, we developed both ELISAs
81 and neutralization assays based on a MPXV isolate from a Dutch patient, to address three
82 crucial questions: (1) are antibodies induced by historic smallpox vaccination cross-reactive
83 with MPXV, (2) do MPXV-infected individuals rapidly mount neutralizing antibody responses,
84 and (3) does MVA-BN vaccination induce MPXV-reactive and neutralizing antibodies?
85

86 Results

87

88 **VACV-reactive antibodies detected >70 years after historic smallpox vaccination cross-**

89 **neutralize MPXV.** To determine whether we could detect VACV-reactive IgG antibodies

90 induced by historic smallpox vaccination, we first performed an ELISA with VACV-infected cell

91 lysate and sera selected from the Erasmus MC biobank based on year of birth, and divided

92 over decades ≤ 1974 (N=56) and >1974 (N=52) (smallpox vaccination was stopped in 1974 in

93 the Netherlands). Sera were all obtained in 2022, meaning that the sera from individuals born

94 prior to 1950 were >70 years post historic smallpox vaccination (median years between

95 sample and birth was 74 years, range 73 – 85 years). VACV-reactive antibodies were

96 frequently detected in sera obtained from individuals born prior to 1974 (42/59, 71%), but

97 hardly in individuals born after 1974 (2/67, 3%) (**Supplemental Table 1, Supplemental**

98 **Figure 1, Figure 1A**). From the sera tested in ELISA, we randomly selected 21 sera (N=16

99 and N=5 from individuals born ≤ 1974 or >1974 , respectively; colored symbols in **Figure 1A**)

100 to assess the presence or absence of antibodies capable of neutralizing MPXV. Neutralization

101 of MPXV was exclusively detected in the selection of sera from individuals born prior to 1974

102 (**Figure 1B**). Sera not capable of neutralizing MPXV were also negative for VACV-reactive

103 antibodies in ELISA.

104

105 **MPXV infection induces VACV-reactive antibodies and boosts antibody titers induced**

106 **by historic smallpox vaccination.** To determine whether MPXV infection leads to production

107 of VACV-reactive IgG antibodies, we performed an ELISA against a lysate of VACV-infected

108 cells on diagnostic sera submitted to our laboratory for MPXV RT-PCR. We included sera from

109 both MPXV PCR-negative (N=40, of which N=19 sera from individuals born ≤ 1974) and PCR-

110 positive individuals (N=32, of which N=13 sera from individuals born ≤ 1974) (**Supplemental**

111 **Table 2**). In MPXV PCR-negative individuals, VACV-reactive IgG antibodies were exclusively

112 detected in participants born ≤ 1974 (N=10/19, 53%), reflecting antibodies induced by historic

113 smallpox vaccination. In MPXV PCR-positive individuals, from whom sera were exclusively

114 obtained in the early symptomatic phase, VACV-reactive IgG antibodies were detected in

115 individuals born ≤ 1974 (N=10/13, 77%) and >1974 (N=5/19, 26%) (**Supplemental Table 2,**

116 **Supplemental Figure 2, Figure 1C**). Since we had thus far hardly detected VACV-reactive

117 IgG antibodies in individuals born after 1974, we assume that these were induced by MPXV

118 infection. Antibody responses were more frequently detected in MPXV PCR-positive

119 individuals born ≤ 1974 , and the geometric mean antibody level was significantly higher,

120 compared to historic vaccination by itself ($p=0.0082$, Mann-Whitney U test) or MPXV infection

121 by itself ($p=0,0010$, Mann-Whitney U test), indicative of a rapid recall antibody response
122 induced by MPXV infection (**Figure 1C**, green symbols).

123

124 **Antibodies induced or boosted by MPXV infection neutralize MPXV.** We selected 35 sera
125 from MPXV PCR-negative (N=16, of which N=11 were sera from individuals born ≤ 1974) and
126 PCR-positive individuals (N=19, of which N=12 were sera from individuals born ≤ 1974) to
127 assess the presence of antibodies capable of neutralizing MPXV (colored symbols in **Figure**
128 **1C**). Similar to the ELISA results, virus neutralizing activity in sera from PCR-negative
129 individuals was only observed in individuals born ≤ 1974 , reflective of antibodies induced by
130 historic smallpox vaccination (**Figure 1D**, red symbols). MPXV neutralizing antibodies were
131 also detected in sera from MPXV PCR positive individuals born after 1974. Interestingly, the
132 rapid boosting of VACV-reactive IgG antibodies after MPXV infection of individuals born ≤ 1974
133 was not as obvious with respect to MPXV neutralizing antibodies as no significant differences
134 were observed (**Figure 1D**). However, a trend towards higher antibody levels in MPXV PCR-
135 positive individuals born ≤ 1974 was observed when compared to historic vaccination by itself
136 ($p=0.0740$, Mann-Whitney U test). This effect was better visualized when performing a direct
137 comparison between the VACV-reactive IgG antibodies and MPXV neutralizing antibodies,
138 revealing a good correlation between VACV ELISA and MPXV PRNT50 titers (Spearman
139 correlation $r=0.8325$, $p<0.0001$) with the exception of a cluster of sera obtained from
140 exclusively MPXV-infected individuals (**Figure 1E**, green triangles).

141

142 **Imvanex vaccination induces VACV-reactive IgG antibodies.** To determine whether
143 Imvanex vaccination leads to the production of VACV-reactive IgG antibodies, we performed
144 an ELISA with a lysate of VACV-infected cells and sera obtained pre-vaccination, 2 and 4
145 weeks after the first vaccination, and 4 weeks after the second vaccination. Participants were
146 vaccinated with the advised dose, 0.5ml with no less than 5×10^7 plaque forming units (pfu).
147 A total of 18 study participants were included (N=3 born ≤ 1974), of which 11 were followed
148 until the last time-point at the time of writing (**Supplemental Table 3, Supplemental Figure**
149 **3**). VACV-reactive IgG antibodies were detected in all sera from study subjects born ≤ 1974 on
150 all time points. A clear boosting by vaccination was not observed in these three individuals,
151 who already had high binding-antibody levels prior to vaccination (**Figure 2A** left panel,
152 compare to **Figure 1A**). In study subjects born >1974 , a gradual increase in binding antibody
153 responses was seen, with detectable antibodies in 1/10 (10%) sera obtained 2 weeks after
154 the first vaccination, 6/11 (55%) sera obtained 4 weeks after the first vaccination, and 8/8 sera
155 obtained 4 weeks after the second vaccination (**Supplemental Table 3 and Figure 2A**).

156

157 **Imvanex vaccination induces low levels of MPXV neutralizing antibodies.** In addition to
158 performing an ELISA with a VACV-infected cell lysate, both MVA and MPXV neutralization
159 assays were performed with sera from Imvanex-vaccinated study subjects. Both MVA and
160 MPXV neutralizing antibodies were detected in study subjects born ≤ 1974 at all timepoints,
161 also prior to Imvanex vaccination (**Figure 2B** and **2C**, left panels). Similar to the VACV-reactive
162 binding antibodies, MVA neutralizing antibodies were induced by vaccination and increased
163 over time in participants born after 1974. Pre-vaccination, 0/6 sera had detectable MVA-
164 neutralizing antibodies, increasing to 5/8 and 8/8 after the first and second vaccination,
165 respectively (**Figure 2B**, right panel). In contrast, MPXV-neutralizing antibodies after
166 vaccination with Imvanex were detected less frequently. Only in five out of eight sera MPXV
167 neutralizing antibodies were detected 4 weeks after the first, but also the second vaccination.
168 Antibody levels in some vaccinees increased after the second shot, but in general little
169 increase in MPXV neutralization was observed after the second shot (**Figure 2C**, right panel).
170

171 **A third MVA vaccination 1 year after completion of the primary regimen significantly**
172 **boosts VACV-reactive antibodies.** To further assess MVA immunogenicity, we performed
173 an ELISA with a lysate of VACV-infected cells and sera from an MVA-H5 influenza vaccination
174 trial.¹² Sera were obtained from study subjects (who were all born > 1974) who received
175 vaccinations following two different regimens: (1) single shot primary vaccination regimen
176 followed by a boost after 1 year, or (2) two shots primary vaccination regimen followed by a
177 boost after 1 year. Additionally, participants received either a high (10^8 pfu) or low (10^7 pfu)
178 dose of MVA-H5. Sera were always obtained 4 weeks after vaccination (**Figure 2D**, top
179 legend). We observed similar levels of VACV-reactive antibodies 4 weeks after 2 shots of
180 Imvanex or MVA-H5 (compare **Figure 2D** with **2A**). As for dosing, we found that vaccination
181 with a high dose resulted in more binding antibodies: 3.7-fold higher binding antibody levels
182 when comparing 2 shots of 10^8 with 2 shots of 10^7 , and 1.8-fold and 2.2-fold higher binding
183 antibody levels when comparing the booster vaccination after a 2 shot or 1 shot primary
184 regimen, respectively (**Supplemental Figure 4**, **Figure 2D**). Additionally, the second
185 vaccination is important for reaching detectable antibody levels, as individuals in a single shot
186 regimen hardly developed antibody responses 4 and 8 weeks after vaccination. Finally, a third
187 vaccination given after 1 year boosted the binding antibody levels in all dosing groups (10-
188 and 19-fold in the 2 shot regimen for 10^8 or 10^7 dose respectively, over 50-fold for both doses
189 in the 1 shot regimen) (**Supplemental Table 4** and **Figure 2D**).

190
191 **ELISAs with VACV-infected cell lysate and PRNTs against MPXV grown on Calu-3 cells**
192 **are most sensitive for antibody detection.** Thus far, we assessed the presence of binding
193 and neutralizing antibodies in sera with an ELISA against a VACV-infected cell lysate and

194 PRNTs with infectious MPXV grown on Calu-3 cells. We additionally developed an ELISA with
195 a MPXV-infected cell lysate, and directly compared the 30% endpoint titers obtained from
196 either the VACV or MPXV ELISA for the age-panel, diagnostic panel, and Imvanex panel of
197 sera (**Supplemental Figure 5A**, original data in **Figure 1A, 1C and 1F**). The ELISA with
198 MPXV-infected cell lysate appeared less sensitive, and only detected antibodies if the 30%
199 endpoint titer against VACV was >1000. Additionally, we compared PRNT50 titers against
200 infectious MPXV grown on either Calu-3 or Vero cells for the age-panel and diagnostic panel
201 of sera (**Supplemental Figure 5B**). The PRNT against Vero-grown MPXV was considerably
202 less sensitive, predominantly detecting neutralizing antibodies at PRNT50 values of >640
203 against Calu-3-grown MPXV.
204

205 Discussion

206 Here, we measured MVA-, VACV- and MPXV-reactive binding and neutralizing antibodies in
207 cohorts of historic smallpox-vaccinated, MPXV PCR-positive, MVA-BN-vaccinated, and MVA-
208 H5-vaccinated individuals. For the development and validation of novel assays, an MPXV
209 isolate obtained during the ongoing outbreak was used. MPXV neutralizing antibodies were
210 detected across all cohorts in individuals with MPXV exposure as well as those who received
211 historic (VACV) or recent (MVA-BN or MVA-H5) poxvirus vaccination. A clear boosting effect
212 of MPXV infection on binding antibody levels was observed in previously vaccinated
213 individuals. Simultaneously, this boosting effect was not as apparent for individuals who had
214 received a recent MVA-BN vaccination after historic smallpox vaccination, although there was
215 a trend towards significance. Strikingly, relatively low binding antibody levels were observed
216 after two shots of MVA-BN in individuals without pre-existing poxvirus-specific immune
217 responses, with poor neutralizing capacity.

218
219 Although little is known about the antigenic similarities between poxviruses, MVA-BN
220 immunogenicity has thus far only been assessed by measuring MVA- and VACV-specific
221 antibodies;⁴ cross-reactivity with other poxviruses is often assumed. We argue that for use of
222 this vaccine during an ongoing MPXV outbreak, it is essential to measure functionality of
223 vaccine-induced antibodies against the currently circulating MPXV strain. To assess antigenic
224 similarities between poxviruses and select the most appropriate serological assays for
225 studying MPXV-reactive immune responses, we compared binding and neutralizing activity of
226 sera from infected and/or vaccinated individuals against VACV, MVA, and/or MPXV.
227 Measuring VACV-reactive binding antibodies by ELISA proved sensitive, as serological
228 responses were detected in the majority of sera from participants born prior to 1974, and in
229 the majority of recent vaccinees. Since we did not have access to historic vaccination records,
230 we could not confirm whether people born prior to 1974 were vaccinated against smallpox,
231 how many shots they received, and which vaccine was used. Measuring MPXV-reactive
232 binding antibodies with an in-house developed ELISA proved less sensitive.

233
234 Because the currently used vaccine is based on MVA, properly assessing vaccine
235 immunogenicity should involve measuring both MVA-specific and MPXV cross-reactive
236 neutralizing antibodies. Interestingly, only limited correlation was observed between MVA and
237 MPXV neutralization in MVA-BN-vaccinated individuals, indicative of antigenic differences
238 between these poxviruses. Depending on the research question, this suggests that measuring
239 a combination of both VACV-reactive antibodies, and MVA and MPXV neutralizing antibodies
240 may be required to study vaccine immunogenicity.

241

242 The evidence for cross-protection afforded by VACV or MVA vaccination against MPX is
243 inferred from animal experiments and from observational studies conducted during the period
244 of enhanced surveillance in the endgame of smallpox eradication. In those studies, partial
245 clinical protection was observed. In our study, the individuals born prior to 1974 still had
246 detectable antibodies that neutralized MPXV, yet current epidemiological data suggest limited
247 protection from infection in this age group (diagnostic observations). The primary MVA
248 immunization series in non-primed individuals yielded relatively low levels of neutralizing
249 antibodies, raising the question whether vaccinated individuals are now protected, and what
250 the correlates of protection against MPXV infection are. In non-human primates, depletion
251 studies underlined that antibodies do play an important role against lethal intravenous MPXV
252 challenge,¹³ although both virus-specific antibodies and T-cells were induced by MVA-BN
253 vaccination. At this moment it is unclear what the relatively low MPXV neutralizing titers mean
254 for protection against disease and transmissibility. Finally, by using a serum set from a
255 previously performed MVA-H5 clinical trial, we showed that VACV-reactive antibodies can be
256 further boosted with an additional shot of MVA. This same trial indicates that dose-sparing
257 (10^7 instead of 10^8 pfu) has a negative effect on the serological outcome of vaccination. Cohort
258 studies following vaccinated individuals and including biological sampling are necessary to
259 further assess vaccine efficacy in risk populations and determine correlates of protection for
260 this emerging pathogen.
261

262 **Materials & Methods**

263

264 **Cell culture.** CEF were isolated from 11-day-old chicken embryos (Drost Loosdrecht BV) and
265 passaged once before use. CEF were cultured in virus production serum-free medium (VP-
266 SFM; Gibco) containing penicillin and streptomycin (P/S). Baby hamster kidney 21 (BHK-21)
267 cells were cultured in Dulbecco's modified Eagle medium (DMEM; Lonza) supplemented with
268 10% FBS, 20 mM HEPES, 0.1% CHNaO₃, 0.1 mM nonessential amino acids (NEAA; Lonza),
269 and P/S/L-glutamine (P/S/G). HeLa cells were cultured in DMEM supplemented with 10%
270 FBS, 20 mM HEPES, 0.1% CHNaO₃, and P/S/G. Vero cells were cultured in DMEM
271 (Capricorn Scientific) supplemented with 10% FBS, 20 mM HEPES, and P/S/G. Calu-3 cells
272 were cultured in Opti-MEM + GlutaMAX (Gibco) supplemented with 10% FBS. All cell lines
273 were grown at 37°C in a humidified CO₂ incubator.

274

275 **Generation of rMVA-GFP and VACV-Elstree virus.** rMVA-GFP was generated by
276 homologous recombination as described previously.¹⁴ MVA clonal isolate F6 served as the
277 parental virus for generating rMVA-GFP.¹⁵ Vector plasmid pG06-P11-GFP was used to direct
278 the insertion of GFP under the transcriptional control of the natural vaccinia virus (VACV) late
279 promoter P11 into deletion III site of the MVA genome. Virus stocks were generated in CEF,
280 purified by ultracentrifugation through 36% sucrose, and reconstituted in a 120 mM NaCl
281 10 mM Tris-HCl buffer (pH 7.4). Titer of the rMVA-GFP stock was initially determined by plaque
282 assay on CEF, and was confirmed for PRNT by titration on Vero cells. The stock was validated
283 by PCR, sequencing, and transgene expression in various cell types. The VACV strain Elstree
284 was grown in HeLa cells to serve as ELISA antigen.

285

286 **Generation of MPXV.** MPXV was isolated from a swab taken from a typical pox lesion of an
287 MPX-positive Dutch patient by inoculating Vero cells. The isolate was designated as
288 MPXV_2022_NL001 and is available through the European Virus Archive (EVAg; Ref-SKU:
289 010V-04721). Virus stocks were propagated to passage 3 by inoculating 70-90% confluent
290 Vero and Calu-3 cultures grown in T175 flasks at an MOI of 0.1 in Advanced DMEM/F12
291 (Gibco) supplemented with 10 mM HEPES, 1X GlutaMAX and 1X primocin (AdDF+++). After
292 4 days, when at least 50% of the surface area in the cultures consisted of visible plaques, cells
293 were harvested using a cell scraper and centrifuged at 2000 x g for 2 min. Cell pellets were
294 resuspended in 500 µl Opti-MEM + GlutaMAX and pipetted up and down to mix 10 times using
295 a P1000 tip. Cell suspensions were lysed by freeze-thawing 3 times in a dry-ice ethanol bath,
296 after which lysates were mixed by pipetting up and down 50 times using a P1000 tip. 10 ml
297 Opti-MEM + GlutaMAX were added to the lysates, which were then cleared by centrifugation

298 at 2000 x g for 5 min. Cleared lysates were filtered through a low protein binding 0.45 µm
299 syringe filter (Millipore), aliquoted, and frozen at -80°C. All work with infectious MPXV was
300 performed in a Class II Biosafety Cabinet under BSL-3 conditions.

301

302 **MPXV stock titrations.** Stock titers were determined by preparing 10-fold serial dilutions in
303 AdDF+++. One hundred µl of each dilution was added to Vero cells in a 96-well plate and
304 incubated for 16 hours in a humidified CO₂ incubator at 37°C. Next, cells were fixed in 10%
305 neutral buffered formalin (NBF) for 30 min and permeabilized in 70% ethanol (submerging the
306 entire plate). Cells were then washed in PBS, blocked in 0.6% BSA (Sigma) and 0.1% Triton
307 X-100 (Sigma-Aldrich) in PBS for 30 min, and stained overnight at room temperature with
308 rabbit-anti-VACV-FITC (Abbexa) at a 1:1000 dilution. After washing in PBS, plates were
309 scanned on the Amersham Typhoon Biomolecular Imager (channel Cy2; resolution 10 mm;
310 GE Healthcare). Numbers of infected cells were quantified using ImageQuant TL 8.2 (GE
311 Healthcare).

312

313 **Detection of VACV- or MPXV-specific IgG antibodies by ELISA.** For the detection of VACV
314 or MPXV-specific antibodies, HeLa or Vero cells were mock-treated or infected with VACV-
315 Elstree or MPXV_2022_NL001 at MOI 1 and 0.1, respectively, and harvested in 1% Triton X-
316 100 in PBS supplemented with mini cOmplete EDTA free protease inhibitor (Roche) when
317 complete cytopathic effect was observed. All work with the MPXV lysate was performed under
318 BSL-3 conditions. For ELISA, high-binding 96-well plates (Corning) were coated for 1 h at 37
319 °C with the diluted cell lysates (VACV coating: 1:500; MPXV coating: 1:100) in PBS. The
320 coating concentrations were optimized in coating titration experiments. Coated plates were
321 washed 5 times with PBS supplemented with 0.05% Tween-20 (PBST, Merck) and
322 subsequently blocked for 1 h at 37 °C with blocking buffer (PBST + 2% skim milk powder (w/v,
323 Merck)). Fivefold dilution series of sera in blocking buffer (starting dilution 1:10), were
324 transferred to the lysate-coated plates and incubated overnight at 4 °C. Plates were washed
325 with five times with PBST and incubated for 1 h at 37 °C with HRP-conjugated goat-anti-human
326 IgG (Dako). Afterwards, plates were again washed five times with PBST and incubated for
327 about 15 min with 100 µl TMB peroxidase substrate (SeraCare/KPL) after which the reaction
328 was stopped with an equal volume of 0.5 N H₂SO₄ (Merck). Absorbance was measured at
329 450 nm using a Tecan Infinite F200 or an Anthos 2001 microplate reader and corrected for
330 absorbance at 620 nm. OD₄₅₀ values obtained with mock-infected cell lysates were
331 subtracted from the OD₄₅₀ value obtained with the VACV/MPXV-infected cell lysates to
332 determine a net OD₄₅₀ response. A positive control serum was included on every ELISA
333 plate, generating a min-to-max OD₄₅₀ S-curve. OD₄₅₀ values generated by dilution series
334 per sample were transformed to this control S-curve, and 30% endpoint titers were calculated.

335

336 **Detection of MVA/MPXV-specific neutralizing antibodies by PRNT.** Vero cells were
337 seeded one day prior to the experiment in 96-well plates (Greiner Bio-One) at a density of
338 20,000 cells per well. Sera were heat inactivated for 1 hour at 60°C and subsequently 2-fold
339 serially diluted in AdDF+++ before 1500 PFU of MVA-GFP or 400 PFU of MPXV_2022_NL001
340 in 60 µl were added per well. The final serum dilution in the first column was 1:20. The virus-
341 serum mix was then incubated for 1 h at 37°C before 100 µl of it were added to the Vero cells.
342 The cells were incubated for 24 h (MVA-GFP) or 16 h (MPXV) at 37°C and 5% CO₂ before
343 fixing in 4% paraformaldehyde for 10 min (MVA-GFP) or in 10% NBF for 30 min (MPXV).
344 MPXV-infected samples were furthermore permeabilized in 70% ethanol, followed by a wash
345 with PBS and blocking in 0.6% BSA and 0.1% Triton X-100 in PBS for 30 min before being
346 stained overnight at room temperature with rabbit-anti-VACV-FITC (Abbeva) at a 1:1000
347 dilution. Both MVA and MPXV neutralization assays were washed with PBS prior to nuclear
348 staining with Hoechst33342 (Thermo Fisher). Cells were imaged using the Opera Phenix
349 spinning disk confocal HCS system (Perkin Elmer) equipped with a 10x air objective (NA 0.3)
350 and 405 nm and 488 nm solid state lasers. Hoechst and GFP/FITC were detected using 435-
351 480 nm and 500-550 nm emission filters, respectively. Nine fields per well were imaged
352 covering approximately 50% of the individual wells. The number of infected cells was
353 quantified using the Harmony software (version 4.9, Perkin Elmer). The dilution that would
354 yield 50% reduction of plaques compared with the infection control was estimated by
355 determining the proportionate distance between two dilutions from which an endpoint titer was
356 calculated. When no neutralization was observed, the PRNT₅₀ was given a value of 10.

357

358 **Serum samples and ethics statement.** Serum samples from N=238 participants were
359 included in this study divided over four different cohorts (**Supplemental Table 1-4,**
360 **Supplemental Figure 1-4**). (1) Age-panel cohort. To validate the assays, an anonymized age-
361 panel cohort was used. For this purpose, samples were randomly selected from the diagnostic
362 serum bank at Erasmus MC based on year of birth, excluding immunocompromised patients.
363 In total, N=126 sera obtained in 2022 were included in this cohort (N=59 born in or prior to
364 1974, N=67 born after 1974). The Erasmus MC Medical Ethics Committee waived ethical
365 approval for use of these anonymized samples. (2) Diagnostic cohort. In the Netherlands,
366 diagnostic serum samples were drawn in addition to swab samples for PCR testing from
367 patients suspected for MPXV infection. In total, N=72 anonymized diagnostic sera were
368 included in this study, subdivided in PCR-negative and PCR-positive patients, born either in
369 or prior to 1974 or after 1974. The Erasmus MC Medical Ethics Committee waived ethical
370 approval for use of these anonymized samples. (3) Imvanex cohort. Serum samples were
371 obtained from healthcare workers (HCW) who received Imvanex vaccination for safety

372 reasons as employees of a BLS-3 laboratory. Samples were collected on a biobanking study
373 protocol. The Erasmus MC Medical Ethics Committee gave ethical approval for this work
374 performed as part of the COVA study (ethical permit MEC-2014-398). Longitudinal samples
375 were obtained pre-vaccination, 2 and 4 weeks after the first vaccination, and 4 weeks after the
376 second vaccination. Participants were vaccinated with the prescribed dose, 0.5ml with no less
377 than 5×10^7 plaque forming units (pfu). A total of 18 participants were included (N=3 born
378 ≤ 1974), of which 11 were followed until the last time-point at the time of writing. (4) MVA-H5
379 cohort. The fourth serum panel consisted of samples that were obtained from participants as
380 part of a past clinical phase I vaccination trial with MVA-H5 in two different regimens (**Figure**
381 **2D**), either with a low (10^7) or high dose (10^8).¹² Longitudinal samples were obtained pre-
382 vaccination, 4 weeks after the first vaccination, 4 weeks after the second vaccination or 8
383 weeks after the first vaccination, and 4 weeks after the booster vaccination after 1 year. The
384 Erasmus MC Medical Ethics Committee gave ethical approval for this work performed in the
385 FluVec-H5 study (ethical permit METC NL37002.000.12, Dutch Trial Registry NTR3401). A
386 total of 22 participants were included here, all born after 1974.

387

388 **Data acquisition and statistical analysis.** All samples from each respective experimental
389 panel (age-panel [1], diagnostic panel [2], Imvanex-vaccinated panel [3], and MVA-H5-
390 vaccinated panel [4]) were analyzed simultaneously per assay to counteract batch effects.
391 Moreover, assays were standardized on a reference control that was included on every
392 individual assay plate. For ELISAs with VACV-infected cell lysate, this was a pool of two high-
393 titer sera from individuals who received both historic smallpox and recent Imvanex vaccination.
394 For ELISAs using MPXV-infected cell lysates, this was an individual who received historic
395 smallpox vaccination and had recent MPXV exposure. Neutralization assays included an
396 infection control. The reference samples on every plate were used to generate S-curves
397 (**Supplemental Figure 1-4**) to which the test samples were transformed to calculate 30%
398 endpoint titers (ELISA) or PRNT50 values (neutralization assays) as described above. A
399 statistical comparison within VACV-reactive 30% endpoint titers (**Figure 1C**) and MPXV-
400 neutralizing PRNT50 (**Figure 1D**) was performed using a Mann-Whitney U test. Correlation of
401 VACV-reactive 30% endpoints titers and MPXV-neutralizing PRNT50 was evaluated by
402 Spearman *R*. A *p*-value below 0.0083 was considered significant after Bonferroni correction
403 for multiple comparisons. Statistical evaluation was done with GraphPad Prism v9.02.

404


405 **Acknowledgements**

406 This work was partially funded from European Union's Horizon 2020 Grant ECRAID (grant no
407 965313), in preparation for possible clinical studies and trials following the decision to activate
408 ECRAID to outbreak mode 2. Sequencing work was supported by European Union's Horizon
409 2020 Grant VEO (Grant No. 874735).

410

411 **Figures**

412



413

414

415 **Figure 1. VACV-reactive and MPXV-neutralizing antibodies after historic smallpox vaccination and MPXV**

416 **infection. (A-B) Detection of poxvirus-specific antibodies in an age-panel of sera: (A) Detection of VACV-reactive**

417 **antibodies by ELISA against VACV-infected cell lysate. Sera obtained from individuals born in or prior to 1974**

418 **(circles), or after 1974 (triangles) are merged on the left side of the graph, and shown per decade on the right side**

419 **of the graph. Colored symbols reflect sera selected for neutralization assays. (B) Detection of MPXV neutralizing**

420 **antibodies by plaque reduction neutralization test (PRNT) on a selection of N=21 sera.**

421 **Detection of poxvirus-specific antibodies in a diagnostic panel of sera: (C) Detection of VACV-reactive antibodies by ELISA against**

422 **VACV-infected cell lysate. Sera were obtained from individuals born in or prior to 1974 (circles), or after 1974**

423 **(triangles), who were either PCR-negative (red) or PCR-positive (green). Colored symbols reflect sera selected for**

424 **neutralization assays. (D) Detection of MPXV-neutralizing antibodies by PRNT on a selection of N=35 sera. (E)**

425 **Relationship between VACV-reactive binding and MPXV-neutralizing antibodies by correlating the data from panels**

426 **(C) and (D). 30% endpoint ELISA titers were calculated based on a 5-fold dilution series, after subtraction of OD450**

427 **values against a mock-infected cell lysate, and relative to a positive control. The 50% plaque reduction**


428 **neutralization titer (PRNT50) was calculated on the basis of a 2-fold dilution series relative to an infection control.**

429 **Lines indicate geometric mean; whiskers indicate 95% confidence interval. A Mann-Whitney U test was performed**

430 **to compare VACV-reactive endpoint titers (C) and MPXV neutralizing PRNT50 (D) ($p < 0.0083$ considered significant**

431 **after Bonferroni correction for multiple comparisons), and MPXV neutralizing antibodies were correlated by**

432 **performing Spearman r analysis (excluding the N=5 sera from MPXV-infected individuals born after 1974).**



433

434

435 **Figure 2. VACV-reactive and MPXV-neutralizing antibodies after Imvanex or MVA-H5 vaccination.** (A-C)

436 Detection of poxvirus-specific antibodies in a panel of sera obtained from Imvanex-vaccinated participants. Sera

437 were obtained pre-vaccination and at 3 time points post-vaccination from individuals born in or prior to 1974

438 (circles), or after 1974 (triangles): (A) Detection of VACV-reactive antibodies by ELISA against VACV-infected cell

439 lysate. (B) Detection of MVA-neutralizing antibodies by PRNT on a serum selection of N=33 sera. (C) Detection of

440 MPXV-neutralizing antibodies by PRNT on a serum selection of N=33 sera. (D) Detection of VACV-reactive

441 antibodies by ELISA against VACV-infected cell lysate. Sera were obtained from participants in an MVA-H5

442 vaccination trial, who received either a high (10⁸) or low (10⁷) dose regimen, with 2 (right panel) or 3 (left panel)

443 vaccinations. Vaccination regimens are indicated in the legend above the panel. Lines indicate geometric mean;

444 whiskers indicate geometric standard deviation. Fold differences between geometric mean titers after the second

445 or booster vaccination with 10⁸ or 10⁷ pfu are indicated. 30% endpoint ELISA titers were calculated based on a 5-

446 fold dilution series, after subtraction of OD450 values against a mock-infected cell lysate, and relative to a positive

447 control. The 50% plaque reduction neutralization titer (PRNT50) was calculated on the basis of a 2-fold dilution

448 series relative to an infection control.

449

450 **References**

- 451 1. Thornhill JP, Barkati S, Walmsley S, et al. Monkeypox Virus Infection in Humans
452 across 16 Countries - April-June 2022. *N Engl J Med* 2022;387:679-91.
- 453 2. Wenham C, Eccleston-Turner M. Monkeypox as a PHEIC: implications for global
454 health governance. *Lancet* 2022.
- 455 3. Volz A, Sutter G. Modified Vaccinia Virus Ankara: History, Value in Basic Research,
456 and Current Perspectives for Vaccine Development. *Adv Virus Res* 2017;97:187-243.
- 457 4. Pittman PR, Hahn M, Lee HS, et al. Phase 3 Efficacy Trial of Modified Vaccinia Ankara
458 as a Vaccine against Smallpox. *N Engl J Med* 2019;381:1897-908.
- 459 5. Jezek Z, Grab B, Szczeniowski MV, Paluku KM, Mutombo M. Human monkeypox:
460 secondary attack rates. *Bull World Health Organ* 1988;66:465-70.
- 461 6. Earl PL, Americo JL, Wyatt LS, et al. Immunogenicity of a highly attenuated MVA
462 smallpox vaccine and protection against monkeypox. *Nature* 2004;428:182-5.
- 463 7. Earl PL, Americo JL, Wyatt LS, et al. Rapid protection in a monkeypox model by a
464 single injection of a replication-deficient vaccinia virus. *Proc Natl Acad Sci U S A*
465 2008;105:10889-94.
- 466 8. Stittelaar KJ, van Amerongen G, Kondova I, et al. Modified vaccinia virus Ankara
467 protects macaques against respiratory challenge with monkeypox virus. *J Virol* 2005;79:7845-
468 51.
- 469 9. Kupferschmidt K. Scientists scramble to set up monkeypox vaccine trials. *Science*
470 2022;377:696-7.
- 471 10. Townsend MB, Keckler MS, Patel N, et al. Humoral immunity to smallpox vaccines and
472 monkeypox virus challenge: proteomic assessment and clinical correlations. *J Virol*
473 2013;87:900-11.
- 474 11. Manischewitz J, King LR, Bleckwenn NA, et al. Development of a novel vaccinia-
475 neutralization assay based on reporter-gene expression. *J Infect Dis* 2003;188:440-8.
- 476 12. Kreijtz JH, Goeijenbier M, Moesker FM, et al. Safety and immunogenicity of a modified-
477 vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase
478 1/2a clinical trial. *Lancet Infect Dis* 2014;14:1196-207.
- 479 13. Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced
480 antibodies are necessary and sufficient for protection against monkeypox virus. *Nat Med*
481 2005;11:740-7.
- 482 14. Kremer M, Volz A, Kreijtz JH, Fux R, Lehmann MH, Sutter G. Easy and efficient
483 protocols for working with recombinant vaccinia virus MVA. *Methods Mol Biol* 2012;890:59-
484 92.

485 15. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly
486 attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72 (Pt
487 5):1031-8.
488
489

490 SUPPLEMENTAL MATERIAL BELONGING TO

491

492 **Low levels of monkeypox virus neutralizing antibodies after MVA-BN**
493 **vaccination in healthy individuals**

494

495 Luca M. Zaeck^{1#}, Mart M. Lamers^{1#}, Babs E. Verstrepen^{1#}, Theo M. Bestebroer¹, Martin E. van
496 Royen², Hannelore Götz³, Marc C. Shamier¹, Leanne P.M. van Leeuwen¹, Katharina S.
497 Schmitz¹, Kimberley Alblas¹, Suzanne van Efferen¹, Susanne Bogers¹, Sandra Scherbeijn¹,
498 Guus F. Rimmelzwaan⁴, Eric C.M. van Gorp¹, Marion P.G. Koopmans^{1\$}, Bart L. Haagmans^{1\$},
499 Corine H. GeurtsvanKessel^{1\$*}, and Rory D. de Vries^{1\$}

500

501 ¹ Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands

502 ² Department of Pathology, Erasmus University Medical Center, Rotterdam, the Netherlands

503 ³ Department Infectious Disease Control, Municipal Public Health Service Rotterdam-Rijnmond (GGD Rotterdam),
504 Rotterdam, the Netherlands

505 ⁴ Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Hannover,
506 Germany

507

508 # authors contributed equally


509 \$ authors contributed equally

510 * corresponding author: Corine H. GeurtsvanKessel, c.geurtsvankessel@erasmusmc.nl

511

512 **Supplemental Figures**

513




514

515

516 **Supplemental Figure 1. Normalized S-curves for determining the 30% OD450 ELISA endpoint in age-panel**
517 **sera.** Sera from the age-panel were 5-fold diluted starting at a dilution of 1:10 and added to plates coated with a
518 VACV-infected cell lysate. A positive reference control was included on every plate to generate an S-curve with
519 minimum (0%) and maximum (100%) OD450 values. All sample OD450 values were normalized to the positive
520 control on the respective plate and plotted as log (inhibitor) vs response curve with four parameter variable slope
521 using GraphPad Prism 9.02. A 30% endpoint dilution was estimated by calculating the proportionate distance
522 between two dilutions, from which a titer was determined. Symbols indicate individual donors, gray lines represent
523 samples from the age-panel, purple lines represent the controls from the different plates. 30% endpoint titers are
524 shown in **Figure 1A**. All samples from this serum panel were run in the same experiment, avoiding any possible
525 batch effects.

526

527




528

529


530 **Supplemental Figure 2. Normalized S-curves for determining the 30% OD450 ELISA endpoint in diagnostic**
531 **sera.** Sera from the diagnostic panel were 5-fold diluted starting at a dilution of 1:10 and added to plates coated
532 with a VACV-infected cell lysate. A positive reference control was included on every plate to generate an S-curve
533 with minimum (0%) and maximum (100%) OD450 values. All 'sample' OD450 values were normalized to the
534 positive control on the respective plate and plotted as log (inhibitor) vs response curve with four parameter variable
535 slope using GraphPad Prism 9.02. A 30% endpoint dilution was estimated by calculating the proportionate distance
536 between two dilutions, from which a titer was determined. Symbols indicate individual donors (circle: born prior to
537 1974, triangle born after 1974), red lines represent sera from PCR-negative donors, green lines represent sera
538 from PCR-positive donors, and purple lines represent the controls from the different plates. 30% endpoint titers are
539 shown in **Figure 1C**. All samples from this serum panel were run in the same experiment, avoiding any possible
540 batch effects.

541



542
543
544
545
546
547
548
549
550
551
552
553
554

Supplemental Figure 3. Normalized S-curves for determining the 30% OD450 ELISA endpoint in Imvanex sera. Sera from the Imvanex panel were 5-fold diluted starting at a dilution of 1:10 and added to plates coated with a VACV-infected cell lysate. A positive reference control was included on every plate to generate an S-curve with minimum (0%) and maximum (100%) OD450 values. All' sample' OD450 values were normalized to the positive control on the respective plate and plotted as log (inhibitor) vs response curve with four parameter variable slope using GraphPad Prism 9.02. A 30% endpoint dilution was estimated by calculating the proportionate distance between two dilutions, from which a titer was determined. Symbols indicate individual donors (circle: born prior to 1974, triangle born after 1974), cyan lines represent sera from Imvanex-vaccinated donors, purple lines represent the controls from the different plates. 30% endpoint titers are shown in **Figure 2A**. All samples from this serum panel were run in the same experiment, avoiding any possible batch effects.



555

556

557 **Supplemental Figure 4. Normalized S-curves for determining the 30% OD450 ELISA endpoint in MVA-H5**

558 **sera.** Sera from the MVA-H5 panel were 5-fold diluted starting at a dilution of 1:10 and added to plates coated with

559 a VACV-infected cell lysate. A positive reference control was included on every plate to generate an S-curve with

560 minimum (0%) and maximum (100%) OD450 values. All' sample' OD450 values were normalized to the positive

561 control on the respective plate and plotted as log (inhibitor) vs response curve with four parameter variable slope

562 using GraphPad Prism 9.02. A 30% endpoint dilution was estimated by calculating the proportionate distance


563 between two dilutions, from which a titer was determined. Symbols indicate individual donors, blue lines represent

564 sera from MVA-H5-vaccinated donors, purple lines represent the controls from the different plates. 30% endpoint

565 titers are shown in **Figure 2D**. All samples from this serum panel were run in the same experiment, avoiding any

566 possible batch effects.

567



568

569

570

571

572

573

574

575

576

577

578

Supplemental Figure 5. Correlation between ELISAs with VACV and MPXV antigen, and neutralization assays with MPXV grown on Vero or Calu-3 cells. (A) ELISAs were performed on the age-panel, diagnostic panel, and Imvanex panel of sera against a VACV-infected or MPXV-infected cell lysate. 30% endpoint ELISA titers were calculated based on a 5-fold dilution series, after subtraction of OD450 values against a mock-infected cell lysate, and relative to a positive control. (B) PRNTs were performed with an MPXV stock grown on either Calu-3 or Vero cells. The 50% plaque reduction neutralization titer (PRNT50) was calculated on the basis of a 2-fold dilution series relative to an infection control. Sera were obtained from individuals born in or prior to (circles), or after (triangles) 1974, who were either PCR-negative (red and gray) or PCR-positive (green).

579 **Supplemental Tables**

580

581 **Supplemental Table 1.** Overview of age-panel sera assessed for the presence of vaccinia virus (VACV)-reactive
582 antibodies by ELISA and monkeypox virus (MPXV)-neutralizing antibodies by plaque reduction neutralization test
583 (PRNT).

| | | <1974 | >1974 | <1950 | 1950-1959 | 1960-1969 | 1970-1974 | 1975-1979 | 1980-1989 | 1990-1999 | >2000 |
|---------------|---------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|------------------|
| | YOB (median, range) | 1961 (1936-1973) | 1992 (1975-2007) | 1948 (1936-1949) | 1954 (1950-1959) | 1964 (1960-1969) | 1971 (1970-1973) | 1976 (1975-1979) | 1984 (1980-1989) | 1993 (1990-1999) | 2005 (2001-2007) |
| VACV-ELISA | Sera | 59 | 67 | 11 | 15 | 19 | 14 | 4 | 25 | 27 | 11 |
| | Responder | 42 | 2 | 8 | 8 | 16 | 10 | 0 | 0 | 1 | 1 |
| | Percentage | 71% | 3% | 73% | 53% | 84% | 71% | 0% | 0% | 4% | 9% |
| MPXVcalu_NEUT | Sera | 16 | 5 | | | | | | | | |
| | Responder | 12 | 0 | | | | | | | | |
| | Percentage | 75% | 0% | | | | | | | | |

584

585

586 **Supplemental Table 2.** Overview of diagnostic panel sera assessed for the presence of vaccinia virus (VACV)-
 587 reactive antibodies by ELISA and monkeypox virus (MPXV)-neutralizing antibodies by plaque reduction
 588 neutralization test (PRNT).

| | | <1974 | | >1974 | |
|---------------------|-------------------|--------------|--------------|--------------|--------------|
| | | PCR-negative | PCR-positive | PCR-negative | PCR-positive |
| VACV_ELISA | Sera | 19 | 13 | 21 | 19 |
| | Responder | 10 | 10 | 0 | 5 |
| | Percentage | 53% | 77% | 0% | 26% |
| MPXcalu_NEUT | Sera | 11 | 12 | 5 | 7 |
| | Responder | 7 | 10 | 0 | 5 |
| | Percentage | 64% | 83% | 0% | 71% |

589
 590

591 **Supplemental Table 3.** Overview of Imvanex panel sera assessed for the presence of vaccinia virus (VACV)-
 592 reactive antibodies by ELISA and modified vaccinia virus Ankara (MVA) and monkeypox virus (MPXV)-neutralizing
 593 antibodies by plaque reduction neutralization test (PRNT).

| | | <1974 | | | | >1974 | | | |
|--------------|------------|-------|-------------|-------------|-------------|-------|-------------|-------------|-------------|
| | | preVx | postVx1_2wk | postVx1_4wk | postVx2_4wk | preVx | postVx1_2wk | postVx1_4wk | postVx2_4wk |
| VACV_ELISA | Sera | 3 | 3 | 2 | 3 | 15 | 10 | 11 | 8 |
| | Responder | 3 | 3 | 2 | 3 | 1 | 1 | 6 | 8 |
| | Percentage | 100% | 100% | 100% | 100% | 7% | 10% | 55% | 100% |
| MVA_NEUT | Sera | 3 | 3 | 2 | 3 | 6 | 0 | 8 | 8 |
| | Responder | 3 | 3 | 2 | 3 | 0 | 0 | 5 | 8 |
| | Percentage | 100% | 100% | 100% | 100% | 0% | #DIV/0! | 63% | 100% |
| MPXcalu_NEUT | Sera | 3 | 3 | 2 | 3 | 6 | 0 | 8 | 8 |
| | Responder | 3 | 3 | 2 | 3 | 1 | 0 | 5 | 5 |
| | Percentage | 100% | 100% | 100% | 100% | 17% | #DIV/0! | 63% | 63% |

594

595

596 **Supplemental Table 4.** Overview of MVA-H5 panel sera assessed for the presence of vaccinia virus (VACV)-
 597 reactive antibodies by ELISA. (A) Responder rates in the 2 shot regimen. (B) Responder rates in the 1 shot regimen.
 598

| A | | 10 ⁸ pfu MVA-H5 (2 shots) | | | | 10 ⁷ pfu MVA-H5 (2 shots) | | | |
|-------------------|-------------------|--------------------------------------|-------------|-------------|-------------|--------------------------------------|-------------|-------------|-------------|
| | | preVx | postVx1_4wk | postVx2_4wk | postVx3_4wk | preVx | postVx1_4wk | postVx2_4wk | postVx3_4wk |
| VACV_ELISA | Sera | 0 | 7 | 2 | 9 | 6 | 5 | 10 | 3 |
| | Responder | 0 | 1 | 2 | 9 | 0 | 0 | 6 | 3 |
| | Percentage | #DIV/0! | 14% | 100% | 100% | 0% | 0% | 60% | 100% |
| B | | 10 ⁸ pfu MVA-H5 (1 shots) | | | | 10 ⁷ pfu MVA-H5 (1 shots) | | | |
| | | preVx | postVx1_4wk | postVx1_8wk | postVx2_4wk | preVx | postVx1_4wk | postVx1_8wk | postVx2_4wk |
| VACV_ELISA | Sera | 9 | 2 | 8 | 1 | 5 | 8 | 2 | 9 |
| | Responder | 0 | 0 | 6 | 1 | 0 | 4 | 1 | 9 |
| | Percentage | 0% | 0% | 75% | 100% | 0% | 50% | 50% | 100% |

599
 600